HIV Coinfection
  • Featured content
    Led by Tram T. Tran, MD, a panel of experts discusses their approach to individualizing initial HCV therapy based on key disease and patient characteristics that have an impact on treatment choice, including HCV genotype, race, cirrhosis, comorbidities, and comedications.
  • Featured content
    Watch Mark S. Sulkowski, MD; Ira M. Jacobson, MD; and Nancy Reau, MD, FAASLD, AGAF, discuss evolving clinical data on the management of HCV infection in harder-to-treat patient populations, including patients with compensated or decompensated cirrhosis, renal impairment, genotype 3 HCV infection, and HIV coinfection.
  • Featured content
    In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
    Date Posted: 5/11/2015
  • Featured content
    In this expert analysis, Jordan J. Feld, MD, MPH; Paul Y. Kwo, MD; and Stefan Zeuzem, MD, discuss the most clinically relevant data on the management of hepatitis C infection in patients with advanced liver disease, cirrhosis, liver transplantation, and HIV coinfection, as well as new advances in the treatment of hepatitis D infection.
  • With a new generation of all-oral HCV therapies entering clinical practice, keeping alert to potential interactions with antiretrovirals and other common medications is part and parcel of managing patients with HIV/HCV coinfection
    Date Posted: 12/29/2014
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 31 Shown
10 of 31 Shown
Show 10 More